trending Market Intelligence /marketintelligence/en/news-insights/trending/TT8G93wln-2e4kCzD_c15A2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Fennec drug to lower chemo-induced hearing loss meets main goal in phase 3 trial

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Fennec drug to lower chemo-induced hearing loss meets main goal in phase 3 trial

Fennec Pharmaceuticals Inc. said the phase 3 trial of Pedmark met its main goal in reducing cisplatin-induced hearing loss in children being treated for an uncommon form of malignant liver cancer.

The SIOPEL 6 study conducted in 99 patients with standard risk hepatoblastoma showed that the addition of Pedmark to chemotherapy drug cisplatin significantly reduced the incidence of hearing loss without any evidence of tumor protection.

Among the patients treated with the combination of cisplatin and Pedmark, 37% suffered hearing loss, compared with 67% of patients who received cisplatin alone.

The combination also demonstrated an 82.1% event free survival with a 98.2% overall survival, versus 78.8% and 92.3%, respectively, for the chemotherapy alone.

Fennec said it will seek regulatory approval for the drug based on the data from the trial along with proof of principle data from the Clinical Oncology Group Protocol ACCL0431.